Recent performance snapshot for Natera (NTRA)

Natera (NTRA) has been volatile in recent trading, with the stock down 3.1% over the past day and 3.6% over the past week, roughly flat over the past month, and up 8.7% over the past 3 months.

Over longer horizons, Natera shows mixed results, with the stock down 5.9% year to date while delivering a 31.5% total return over the past year, a very large total return over the past 3 years, and a 107.3% total return over the past 5 years.

Recent trading has cooled after a very large 3 year total shareholder return, with the stock down over the year to date but still supported by a 1 year total shareholder return above 30%. This suggests momentum has eased but not fully reversed.

If you are interested in other healthcare and diagnostics companies using artificial intelligence, it could be a good moment to scan the market through 39 healthcare AI stocks

With Natera now worth about US$31.8b and the stock trading around US$215, recent gains and continuing losses leave a key question for investors: is there still mispricing here or is the market already baking in future growth?

Most Popular Narrative: 18% Undervalued

The most followed narrative pegs Natera's fair value at about $260.89 per share, above the last close of $215.31, and ties that gap to a detailed earnings and margin roadmap.

Analysts expect earnings to reach $209.6 million (and earnings per share of $1.59) by about May 2029, up from $226.3 million of losses today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $771.6 million in earnings, and the most bearish expecting $235.6 million of losses.

Interested in what has to happen between now and 2029 to support that valuation? The narrative leans heavily on faster revenue growth, rising margins, and a premium future earnings multiple that sits well above the wider biotech sector.

Result: Fair Value of $260.89 (UNDERVALUED)

However, you still need to weigh the risk that high R&D and commercial spending keeps profitability under pressure, and that tougher reimbursement decisions cap revenue progress.

Another Angle on Valuation: Price to Sales Looks Stretched

The analyst narrative focuses on earnings and long term fair value, but current trading tells a different story. At around 12.3x P/S, Natera sits above the US Biotechs industry average of 10.1x, its peer average of 11.7x, and an estimated fair ratio of 8.3x. This raises the question of how much optimism is already in the price.

For a closer look at how this pricing gap compares with peers and where the ratio could move over time, check the detailed valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals on value and risk so far? Use that tension as a prompt to move quickly, review the full picture, and weigh both sides with the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop with a single stock. Broaden your watchlist now using focused screeners that surface opportunities by quality, value, and resilience.

• Target quality at a discount by scanning companies that combine strong fundamentals with appealing valuations through the 49 high quality undervalued stocks.
• Prioritise resilience by filtering for businesses with sturdy finances using the solid balance sheet and fundamentals stocks screener (46 results).
• Spot potential future leaders early by reviewing a curated screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.